Étiquette : trouble mental

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders, Giovanna Felipe Cavalcante e Costa et al., 2018

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders Giovanna Felipe Cavalcante e Costa, Hisao Nishijo, Leonardo Ferreira Caixeta, and Tales Alexandre Aversi-Ferreira Hindawi - Evidence-Based Complementary and Alternative Medicine, Volume 2018, Article ID 7686913, 27 pages Doi : 10.1155/2018/7686913   Abstract For neurological disorders, pharmacological tests have shown promising results in the reduction of side effects when using plants with known therapeutic effects in the treatment of some types of dementia. Therefore, the goals of this study are to gather data about the major medicinal plants used in the nervous system as described in ethnopharmacological surveys from South [...]

Lire la suite

Modulation of Social Cognition via Hallucinogens and “Entactogens”, Katrin H. Preller and Franz X. Vollenweider, 2019

Modulation of Social Cognition via Hallucinogens and “Entactogens” Katrin H. Preller and Franz X. Vollenweider Frontiers in Psychiatry, décembre 2019 doi: 10.3389/fpsyt.2019.00881 Social cognition is a fundamental ability in human everyday lives. Deficits in social functioning also represent a core aspect of many psychiatric disorders. Yet, despite its significance, deficits in social cognition skills are insufficiently targeted by current treatments. Hallucinogens and entactogens have been shown to have the potential to modulate social processing. This article reviews the literature on the influence of hallucinogens and entactogens on social processing in controlled experimental studies in humans and elucidates the underlying neurobiological and neuropharmacological mechanisms. Furthermore, [...]

Lire la suite

Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland, Yasmin Schmid et al., 2019

Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland Yasmin Schmid, Irene Scholz, Laura Mueller, Aristomenis K. Exadaktylos, Alessandro Ceschi, Matthias E. Liechti, Evangelia Liakoni Drug and Alcohol Dependence, 2019. https://doi.org/10.1016/j.drugalcdep.2019.107726   A B S T R A C T Background : Concomitant use of cannabis and other psychoactive substances is common and it is often difficult to differentiate its acute effects from those of other substances. This study aimed to characterize the acute toxicity of cannabis with and without co-use of other substances. Methods : Retrospective analysis of cases presenting at the emergency departments of three large hospitals in Switzerland due [...]

Lire la suite

Adolescent Cannabis Use : What is the Evidence for Functional Brain Alteration ?, V. Lorenzetti et al., 2016

Adolescent Cannabis Use : What is the Evidence for Functional Brain Alteration ? V. Lorenzetti, S. Alonso-Lanaa, G. J. Youssef, A. Verdejo-Garcia, C. Suo, J. Cousijn, M. Takagi, M. Yücel and N. Solowij Current Pharmaceutical Design, 2016, 22, 1-14. DOI: 10.2174/1381612822666160805155922   Abstract Background : Cannabis use typically commences during adolescence, a period during which the brain undergoes profound remodeling in areas that are high in cannabinoid receptors and that mediate cognitive control and emotion regulation. It is therefore important to determine the impact of adolescent cannabis use on brain function. Objective : We investigate the impact of adolescent cannabis use on brain function by reviewing the functional [...]

Lire la suite

Prevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness receiving treatment for Alcohol Use Disorders, Jordan Skalisky et al., 2017

Prevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness receiving treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, 1, 133-138. Doi : 10.1089/can.2017.0006   Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]

Lire la suite

Psychedelics : Where we are now, why we got here, what we must do, Sean J. Belouin & Jack E. Henningfield, 2018

Psychedelics : Where we are now, why we got here, what we must do Sean J. Belouin, Jack E. Henningfield Neuropharmacology, 2018, 142, 7e19 https://doi.org/10.1016/j.neuropharm.2018.02.018 a b s t r a c t The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the discovery of lysergic acid diethylamide (LSD) and its promising development as a treatment for several types of mental illnesses during the 1940s. This was [...]

Lire la suite

Psychiatry & the psychedelic drugs. Past, present & future, James J.H. Rucker et al., 2018

Psychiatry & the psychedelic drugs. Past, present & future James J.H. Rucker, Jonathan Iliff, David J. Nutt Neuropharmacology, 2018, 142, 200e218 https://doi.org/10.1016/j.neuropharm.2017.12.040   a b s t r a c t The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called ‘psychoneurotic’ disorders sometimes benefited considerably from their tendency to [...]

Lire la suite

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings, Sonja ELSAID, 2019

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Molecular Basis of Neuropsychiatric Disorders : from Bench to Bedside Sonja ELSAID, Stefan KLOIBER, Bernard Le FOLL Progress in Molecular Biology and Translational Science, 2019, 167, 25-75. doi : 10.1016/bs.pmbts.2019.06.005. Cannabis sativa (cannabis) is on of the oldest plants cultivated by men. Cannabidiol (CBD) is the major non-psychomimetic compound derived from cannabis. It has been proposed to have a therapeutic potential over a wide range of neuropsychiatric disorders. In this narrative review, we have summarized a selected number of pre-clinical and clinical studies, examining the effects of CBD in neuropsychiatric [...]

Lire la suite

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry, Gioacchino Calapai et al., 2019

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry Gioacchino Calapai, Carmen Mannucci, Ioanna Chinou, Luigi Cardia, Fabrizio Calapai, Emanuela Elisa Sorbara, Bernardo Firenzuoli, Valdo Ricca, Gian Franco Gensini and Fabio Firenzuoli Hindawi - Evidence-Based Complementary and Alternative Medicine, 2019, Article ID 2509129, 11 pages https://doi.org/10.1155/2019/2509129   Background : Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective. &e aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD [...]

Lire la suite

Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids, E. Appiah-Kusi et al., 2019

Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids E. Appiah-Kusi, R. Wilson, M.Colizzi, E. Foglia, Sagnik Bhattacharyya, et al. Psychological Medicine, 2019. DOI: https://doi.org/10.1017/S0033291719001946 Published online by Cambridge University Press: 19 August 2019 Abstract BackgroundEvidence has been accumulating regarding alterations in components of the endocannabinoid system in patients with psychosis. Of all the putative risk factors associated with psychosis, being at clinical high-risk for psychosis (CHR) has the strongest association with the onset of psychosis, and exposure to childhood trauma has been linked to an increased risk of development of psychotic disorder. We aimed to investigate whether being at-risk for [...]

Lire la suite